Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006734 · ClinicalTrials.gov registry record · Phase 3
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
A Phase 3 study of Sarcoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 587
- Enrollment target
- 20
- Study locations
NCT00006734: Completed Phase 3 study of Sarcoma, sponsored by Children's Oncology Group.
NCT00006734 is a Phase 3 study of Sarcoma that has completed, run by Children's Oncology Group. The registered enrollment target is 587 participants, below the 916-participant average among 122 other Sarcoma trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006734, a Phase 3 study of Sarcoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 587 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor. PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy and/or surgery in treating patients who have Ewing's sarcoma or primitive neuroectodermal tumor.
Primary Outcome
Assessed using a two sided log rank test of 0.05.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
Study Locations (20)
California
- Southern California Permanente Medical Group - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center - Los Angeles
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
- Children's Hospital Central California - Madera
- Children's Hospital and Research Center at Oakland - Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
- Children's Hospital of Orange County - Orange
- Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
- Sutter Cancer Center - Sacramento
- University of California Davis Cancer Center - Sacramento
Alabama
- Comprehensive Cancer Center at University of Alabama at Birmingham - Birmingham
- University of South Alabama Cancer Research Institute - Mobile
Arizona
- Phoenix Children's Hospital - Phoenix
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 2001-05 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
What the finished NCT00006734 record still lists
NCT00006734 is an interventional study that assigns participants to a tested intervention. The registered 587 participants enrollment target is mid-sized for trials with a published cap, below the 916-participant average among 122 other Sarcoma trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00006734 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00006734 about?
NCT00006734 is a clinical study titled "Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective...
What is the current status of trial NCT00006734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2001-05. Estimated completion is 2023-06-30.
What conditions does trial NCT00006734 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00006734?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006734?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006734 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006734's enrollment target sits among peer trials
587 13th of 122 higher than 110 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
COMPLETED · Phase 3
-
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus
COMPLETED · Phase 3
-
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921603 · 588 participants · NA
POCUS-Guided Diuresis for Decompensated Heart Failure
- NCT06986954 · 588 participants
Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia